Here are the 10-K annual reports from Agios Pharmaceuticals, Inc. (AGIO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AGIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGIO filings page.
Agios Pharmaceuticals is a commercial-stage biopharma focused on rare hematology, built around the PK activator mitapivat, sold as PYRUKYND® for pyruvate kinase deficiency and AQVESME™ for thalassemia. AQVESME™ received FDA approval in December 2025 for anemia in adults with non‑transfusion‑dependent and transfusion‑dependent alpha- or beta‑thalassemia, with a U.S. launch in January 2026 under a REMS requiring intensive liver monitoring.
For the year ended December 31, 2025, Agios reported a net loss of $412.8 million, compared with net income of $673.7 million in 2024, when results were boosted by a $905.0 million sale of vorasidenib royalty rights and a $200.0 million milestone payment. As of December 31, 2025, accumulated deficit was $561.7 million, and as of February 6, 2026, there were 58,592,172 common shares outstanding.
The company is advancing a pipeline that includes tebapivat for lower‑risk myelodysplastic syndromes and sickle cell disease, AG‑181 for phenylketonuria, and AG‑236 (licensed from Alnylam) for polycythemia vera, alongside extensive global intellectual property. Key risks center on successful commercialization of PYRUKYND® and AQVESME™, clinical and regulatory outcomes for mitapivat and other candidates, dependence on third‑party manufacturers and partners, competition in rare diseases, and the need for additional capital if existing resources prove insufficient.